To the Editor:

Bloodstream infections (BSIs) are the most common infections among maintenance hemodialysis patients and are associated with considerable morbidity and mortality. From 2003 to 2012, rates of BSI and sepsis hospitalizations in this patient population increased by 40%. There is a paucity of recent data pertaining to causative pathogens and antimicrobial resistance rates causing BSIs.

From January 1, 2009, to December 31, 2017, a retrospective study was conducted to quantify the trends in pathogens and their antimicrobial-resistant profiles causing BSIs among maintenance hemodialysis patients admitted to a 700-bed and a 255-bed tertiary-care hospital in Providence, RI. Approval from the ethics board was obtained (institutional review board 1158504-5). Due to the use of deidentified patient data, the need for informed consent was waived.

BSIs were identified using Theradoc (Premier, Inc). This clinical surveillance software is used nationwide by infection preventionists to monitor infections within hospitals. Requirement for maintenance hemodialysis was obtained through Theradoc and confirmed by review of electronic medical records. Data for type of hemodialysis access or source of BSI were not available from Theradoc. All positive blood cultures were considered true BSIs, except for coagulase-negative Staphylococcus spp, which required review of the patient’s electronic medical record and documentation of directed treatment by the provider. BSIs were considered hospital acquired if the first positive blood culture was collected 48 hours or longer after admission. Multiple positive blood cultures for the same patient during the same admission were counted as a single BSI.

Antimicrobial susceptibility profiles were obtained from the electronic medical record’s microbiology reports. Clinical and Laboratory Standards Institute’s standards for antimicrobial susceptibility testing were used. Isolates with intermediate resistance to a specific antimicrobial were classified as resistant. Data were analyzed using SAS, version 9.4 (SAS Institute). Cochran-Armitage test for linear trends was used to examine trends in causative pathogens and antimicrobial resistance.

During the study period, a total of 542 BSIs, caused by 559 isolates, were identified among 521 hospitalized maintenance hemodialysis patients. Seventeen (3.1%) BSIs were polymicrobial and 89 (16.4%) were hospital-acquired infections. Pathogen distribution by type is shown in Table 1. Gram-negative bacterial species were Escherichia coli (34.2% of total gram-negative bacteria), Klebsiella spp (20.8%), Pseudomonas aeruginosa (10.7%), Enterobacter spp (10.7%), Serratia spp (6.7%), Acinetobacter spp (4.7%), Stenotrophomonas spp (3.4%), Proteus spp (3.4%), Citrobacter spp (2.7%), Morganella morganii (1.3%), Salmonella spp (0.7%), and Haemophilus spp (0.7%).

There was a statistically significant increase in gram-negative pathogens and decrease in S aureus causing BSIs during the 9-year study period (P = 0.003 and P = 0.002, respectively). There were no statistically significant changes in trends during the study period for specific gram-negative species (P > 0.05). The percent of pathogens resistant to specific antimicrobial or antimicrobial classes per study year is shown in Table 2.

In this 9-year hospital-based study, gram-negative bacteria were the second most common pathogens causing BSIs, after S aureus. Rates of BSI caused by gram-negative bacteria increased during the study period, whereas rates of BSI caused by S aureus decreased. In 2017, the last year of the study, BSIs caused by gram-negative bacteria were more common than those

| Pathogen                  | Total Isolates | 2009 (%) | 2010 (%) | 2011 (%) | 2012 (%) | 2013 (%) | 2014 (%) | 2015 (%) | 2016 (%) | 2017 (%) | P     |
|---------------------------|----------------|----------|----------|----------|----------|----------|----------|----------|----------|----------|-------|
| Staphylococcus aureus      | 252 (45.1%)    | 29 (48.3%)| 37 (43.0%)| 49 (55.1%)| 32 (54.2%)| 30 (65.2%)| 17 (29.3%)| 24 (60.0%)| 21 (29.6%)| 13 (26.0%)| 0.002 |
| Gram-negative bacteria     | 149 (26.7%)    | 15 (25.0%)| 19 (22.1%)| 15 (16.9%)| 14 (23.7%)| 9 (19.6%) | 24 (41.4%)| 9 (22.5%) | 25 (35.2%)| 19 (38.0%)| 0.003 |
| Coagulase-negative Staphylococcus spp | 66 (11.8%) | 6 (10.0%) | 19 (22.1%) | 12 (13.5%) | 3 (5.1%) | 2 (4.3%) | 5 (8.6%) | 0 (0.0%) | 11 (15.5%) | 8 (16.0%) | 0.5   |
| Enterococcus spp           | 46 (8.2%)      | 8 (13.3%) | 3 (5.5%)  | 10 (11.2%)| 1 (1.7%)  | 2 (4.4%) | 7 (12.1%) | 3 (7.5%) | 7 (9.9%)  | 5 (10.0%) | 0.7   |
| Streptococcus spp          | 30 (5.4%)      | 1 (1.7%)  | 3 (5.5%)  | 1 (1.1%)  | 8 (13.6%)| 2 (4.4%) | 4 (6.9%) | 4 (10.0%)| 3 (10.0%)| 4 (8.0%) | 0.08  |
| Fungi*                    | 16 (2.9%)      | 1 (1.7%)  | 5 (8.2%)  | 2 (3.2%)  | 1 (1.7%)  | 1 (2.2%) | 1 (1.7%) | 0 (0.0%) | 4 (5.7%) | 1 (2.0%) | 0.9   |
| Total                     | 559 (100%)     | 60 (100%) | 86 (100%) | 89 (100%) | 59 (100%) | 46 (100%) | 58 (100%) | 40 (100%) | 71 (100%) | 50 (100%) | 0.2   |

*All were identified as Candida spp, except for 1 Cryptococcus sp in 2016.

Table 1. Distribution of Pathogens Associated With Bloodstream Infections Among Hospitalized Maintenance Hemodialysis Patients
**Table 2. Number and Percent of Pathogens That Tested Resistant to Selected Antimicrobials, Per Year of Study**

| Pathogen, Antimicrobial          | 2009          | 2010          | 2011          | 2012          | 2013          | 2014          | 2015          | 2016          | 2017          | P           |
|---------------------------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|-------------|
| **Staphylococcus aureus**        |               |               |               |               |               |               |               |               |               |             |
| Methicillin                     | 16/29 (55.2%) | 19/37 (51.4%) | 29/49 (59.2%) | 11/32 (34.4%) | 16/30 (53.3%) | 6/17 (35.3%)  | 8/24 (33.3%)  | 11/21 (52.4%) | 5/13 (38.5%)  | 0.1         |
| Vancomycin                      | 4/8 (50.0%)   | 2/3 (66.6%)   | 3/10 (30.0%)  | 0/1 (0.0%)    | 1/2 (50.0%)   | 3/7 (42.9%)   | 0/3 (0.0%)    | 1/7 (14.3%)   | 2/5 (40%)     | 0.2         |
| **Enterococcus spp**            |               |               |               |               |               |               |               |               |               |             |
| **Gram-negative bacteria**      |               |               |               |               |               |               |               |               |               |             |
| Aminoglycosides<sup>a</sup>     | 0/15 (0.0%)   | 0/17 (0.0%)   | 3/15 (20.0%)  | 6/14 (42.9%)  | 1/9 (11.1%)   | 4/23 (17.4%)  | 0/9 (0.0%)    | 3/22 (13.6%)  | 3/17 (17.6%)  | 0.4         |
| Extended-spectrum               | 5/14 (35.7%)  | 3/18 (16.7%)  | 2/15 (13.3%)  | 3/14 (21.4%)  | 1/9 (11.1%)   | 2/22 (9.1%)   | 2/9 (22.2%)   | 6/25 (24.0%)  | 7/18 (38.9%)  | 0.5         |
| cephalosporins<sup>b</sup>      |               |               |               |               |               |               |               |               |               |             |
| Meropenem                       | 0/15 (0.0%)   | 1/17 (5.9%)   | 0/15 (0.0%)   | 0/14 (0.0%)   | 0/9 (0.0%)    | 1/22 (4.5%)   | 0/9 (0.0%)    | 0/22 (0.0%)   | 1/17 (5.9%)   | 0.7         |
| Piperacillin/tazobactam         | 2/14 (14.3%)  | 3/18 (16.7%)  | 0/13 (0.0%)   | 3/13 (23.0%)  | 0/9 (0.0%)    | 3/21 (14.3%)  | 1/8 (12.5%)   | 1/25 (4.0%)   | 2/18 (11.1%)  | 0.4         |
| Fluoroquinolones<sup>c</sup>    | 3/15 (20.0%)  | 1/18 (5.5%)   | 3/15 (20.0%)  | 8/14 (57.1%)  | 1/9 (11.1%)   | 5/23 (21.7%)  | 1/9 (11.1%)   | 5/25 (20.0%)  | 3/19 (15.8%)  | 0.9         |
| Multidrug resistant<sup>d</sup> | 2/14 (14.3%)  | 0/17 (0.0%)   | 0/17 (0.0%)   | 3/13 (23.1%)  | 0/9 (0.0%)    | 1/21 (4.8%)   | 0/8 (0.0%)    | 2/22 (9.1%)   | 2/17 (11.8%)  | 0.7         |

<sup>a</sup>Tobramycin and/or gentamicin.
<sup>b</sup>Cefepime, cefazidime, and ceftriaxone.
<sup>c</sup>Ciprofloxacin and levofloxacin.
<sup>d</sup>Resistance to at least 1 antimicrobial in 3 or more antimicrobial categories, which included extended-spectrum cephalosporins, fluoroquinolones, aminoglycosides, meropenem (all organisms); and piperacillin/tazobactam (Enterobacteriaceae and *Pseudomonas aeruginosa*). Denominators represent number of isolates tested to all antimicrobials/classes.

...caused by *S. aureus* (38.0% and 26.0%, respectively). Future studies need to verify the findings of this 2-center study.

The increase in gram-negative pathogens implicated in BSIs among maintenance hemodialysis patients is of great concern because they are commonly associated with severe sepsis and mortality rates of up to 38%.<sup>6,7</sup> Studies have shown that antimicrobial resistance among gram-negative bacteria is also of great concern because rates are rapidly increasing.<sup>7</sup> Resistance to multiple antimicrobials is also frequent and severely limits therapeutic options. For example, infections caused by carbapenemase-producing gram-negative bacteria are resistant to carbapenems, cephalosporins, and many other antimicrobials, leaving polymyxins such as colistin as the only remaining effective antimicrobial.<sup>7</sup>

In the last year of this study, resistance to extended-spectrum cephalosporins, such as cepafime, reached 38.9% among gram-negative bacteria. These antimicrobials are frequently used as empiric treatment for presumed BSIs and therefore these high percentages warrant concern. Furthermore, 11.8% of gram-negative bacteria were resistant to 3 or more antimicrobial classes, including extended-spectrum cephalosporins, fluoroquinolones, and carbapenems. Although an increase in resistance rates was not detected, this is likely due to a small sample size because it is well established that rates are increasing in other patient populations.<sup>7</sup>

Overuse of antimicrobials is one of the main mechanisms for the emergence and spread of antimicrobial-resistant pathogens. Antimicrobial stewardship programs implemented in dialysis facilities have shown substantial reduction in unnecessary antimicrobial prescribing and should be implemented in all facilities.<sup>8</sup> Cross-transmission between patients is another main mechanism of spread and preventive efforts in dialysis facilities predominantly focus on *methicillin-resistant S. aureus* and vancomycin-resistant enterococci.<sup>9</sup> The results of this study suggest that consideration to expand to antimicrobial-resistant gram-negative pathogens may be warranted.

Larger scale studies, such as those conducted by the National Healthcare Safety Network, are needed to fully understand the evolving epidemiology of BSIs among maintenance hemodialysis patients.<sup>1</sup>

**ARTICLE INFORMATION**

**Authors’ Affiliations**: Divisions of Nephrology (QF, DS) and Infectious Diseases (FSG, EMCD), Warren Alpert School of Medicine, Brown University, Providence, RI.

**Address for Correspondence**: Erika M.C. D’Agata, MD, MPH, Division of Infectious Diseases, Brown University, 593 Eddy St, Aldrich 720, Providence, RI 02908. E-mail: edagata@lifespan.org

**Authors’ Contributions**: Research idea and study design: DS, FSG, EMCD; data acquisition: QF, EMCD; data analysis/interpretation: Qadeer Farhan, MD  
Douglas Shemin, MD  
Fizza S. Gillani, PhD  
Erika M.C. D’Agata, MD, MPH
OF, DS, FSG, EMCD; statistical analysis: FSG; supervision or mentorship: DS, EMCD. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.

**Support:** This work was supported by the National Institute of Health’s K24 AI119158 (Dr D’Agata). The funding agency did not have any role in study design; collection, analysis, and interpretation of data; writing the report; or the decision to submit the report for publication.

**Financial Disclosure:** The authors declare that they have no relevant financial interests.

**Peer Review:** Received February 22, 2019. Evaluated by 1 external peer reviewer, with direct editorial input from the Statistical Editor and the Editor-in-Chief. Accepted in revised form April 21, 2019.

**Publication Information:** © 2019 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Published online May 10, 2019 with doi 10.1016/j.xkme.2019.04.005

**REFERENCES**

1. Nguyen DB, Shugart A, Lines C, et al. National Healthcare Safety Network (NHSN) Dialysis Event Surveillance Report for 2014. *Clin J Am Soc Nephrol*. 2017;12(7):1139-1146.
2. Wetmore JB, Li S, Molony JT, et al. Insights from the 2016 Peer Kidney Care Initiative Report: still a ways to go to improve care for dialysis patients. *Am J Kidney Dis*. 2018;71(1):123-132.
3. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: 24th Informational Supplement. Wayne, PA: CLSI; 2014. M100-S24.
4. Magiorakos AP, Srinivasan A, Carey R, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect*. 2012;18(3):268-281.
5. Livorsi DJ, Chorazy ML, Schweizer ML, et al. A systematic review of the epidemiology of carbapenem-resistant Enterobacteriaceae in the United States. *Antimicrob Resist Infect Control*. 2018;7:55-64.
6. Goto M, McDanel JS, Jones MM, et al. Antimicrobial non-susceptibility of gram-negative bloodstream isolates, Veterans Health Administration System, United States, 2003–2013. *Emerg Infect Dis*. 2017;23(11):1815-1825.
7. Marston HD, Dixon DM, Knisely JM, Palmore TN, Fauci AS. Antimicrobial resistance. *JAMA*. 2016;316(11):1193-1204.
8. D’Agata EMC, Lindberg CC, Lindberg CM, et al. The positive effects of an antimicrobial stewardship program targeting outpatient hemodialysis facilities. *Infect Control Hosp Epidemiol*. 2018;39(12):1400-1405.
9. D’Agata EMC. Addressing the problem of multidrug-resistant organisms in dialysis. *Clin J Am Soc Nephrol*. 2018;13(4):666-668.